biostudies-literatureUnknown9(7)Kim JY<h4>Background</h4>EGHB010, a standardized extract of <i>Paeoniae radix</i> and <i>Glycyrrhizae radix</i>, inhibits choroidal neovascularization. The aim of this study is to evaluate the efficacy and safety of EGHB010 on early age-related macular degeneration (AMD) progression inhibition.<h4>Methods</h4>The study was designed as a randomized, double-blind, single-center, placebo-controlled study. Subjects were 50 years of age or older, and early AMD satisfied the criteria of more than 15 small (<63 µm) drusen, less than 20 intermediate (≥63, <125 µm) drusen, or pigment abnormalities. For 12 weeks, the treatment group received EGHB010 and the control received the placebo. The main outcomes were changes in macular pigment optical density (MPOD), central macular thickness (CMT), and central cAnnals of translational medicine541https://www.ebi.ac.uk/biostudies/studies/S-EPMC8105837biostudies-literatureA 12-week, randomized, double-blind, placebo-controlled study assessing the efficacy of EGHB010, a standardized extract of <i>Paeoniae radix</i> and <i>Glycyrrhizae radix</i>, in patients with early age-related macular degeneration.PMC8105837Kim JYPark YHPark WKKim RYKim MfalseA 12-week, randomized, double-blind, placebo-controlled study assessing the efficacy of EGHB010, a standardized extract of <i>Paeoniae radix</i> and <i>Glycyrrhizae radix</i>, in patients with early age-related macular degeneration.<h4>Background</h4>EGHB010, a standardized extract of <i>Paeoniae radix</i> and <i>Glycyrrhizae radix</i>, inhibits choroidal neovascularization. The aim of this study is to evaluate the efficacy and safety of EGHB010 on early age-related macular degeneration (AMD) progression inhibition.<h4>Methods</h4>The study was designed as a randomized, double-blind, single-center, placebo-controlled study. Subjects were 50 years of age or older, and early AMD satisfied the criteria of more than 15 small (<63 µm) drusen, less than 20 intermediate (≥63, <125 µm) drusen, or pigment abnormalities. For 12 weeks, the treatment group received EGHB010 and the control received the placebo. The main outcomes were changes in macular pigment optical density (MPOD), central macular thickness (CMT), and central c2021-01-01T00:00:00Z2021 Apr2025-05-29T16:36:03.014Z2025-05-29T16:36:03.014ZS-EPMC81058373398723910.21037/atm-20-4701